Skip to main content
SpringerLink
Log in

Bedaquiline beats background therapy for drug-resistant TB

  • Meeting report
  • Published:
PharmacoEconomics & Outcomes News

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Notes

  1. Drug costs were in 2014 euros

References

  1. Wolfson L, et al. Cost Effectiveness of Bedaquiline for the Treatment of Multidrug-Resistant Tuberculosis. 17th Annual European Conference of the International Society for Pharmacoeconomics and Outcomes : (plus poster) abstr. PRS43, 8 Nov 2014. Available from: URL: http://www.ispor.org/RESEARCH_STUDY_DIGEST/list.asp?qs=39110.

  2. Wolfson L, et al. Costs and Effectiveness of Combination Therapy with Bedaquiline and Other Anti-Tuberculosis Drugs in Patients with Multi- and Extensively Drug-Resistant Tuberculosis in Germany. 17th Annual European Conference of the International Society for Pharmacoeconomics and Outcomes : (plus poster) abstr. PIN62, 8 Nov 2014. Available from: URL: http://www.ispor.org/RESEARCH_STUDY_DIGEST/list.asp?qs=39362.

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Bedaquiline beats background therapy for drug-resistant TB. PharmacoEcon Outcomes News 717, 16 (2014). https://doi.org/10.1007/s40274-014-1741-y

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40274-014-1741-y

Search

Navigation